Cargando…
Metabolic Clues to Bile Acid Patterns and Prolonged Survival in Patients with Metastatic Soft-Tissue Sarcoma Treated with Trabectedin
Metastatic soft-tissue sarcomas (mSTS) encompass a highly heterogeneous group of rare tumours characterized by different clinical behaviours and outcomes. Currently, prognostic factors for mSTS are very limited, posing significant challenges in predicting patient survival. Within a cohort of 39 mSTS...
Autores principales: | Miolo, Gianmaria, Buonadonna, Angela, Scalone, Simona, Lombardi, Davide, Della Puppa, Lara, Steffan, Agostino, Corona, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608628/ https://www.ncbi.nlm.nih.gov/pubmed/37887360 http://dx.doi.org/10.3390/metabo13101035 |
Ejemplares similares
-
Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients
por: Corona, Giuseppe, et al.
Publicado: (2023) -
Integration of Serum Metabolomics into Clinical Assessment to Improve Outcome Prediction of Metastatic Soft Tissue Sarcoma Patients Treated with Trabectedin
por: Miolo, Gianmaria, et al.
Publicado: (2020) -
Novel metabolomics-biohumoral biomarkers model for predicting survival of metastatic soft-tissue sarcomas
por: Vignoli, Alessia, et al.
Publicado: (2023) -
Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas
por: Buonadonna, Angela, et al.
Publicado: (2023) -
Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)